4-Piperidinamine, 1-[3-(2,3-dichlorophenyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl]-4-methyl-结构式
|
常用名 | 4-Piperidinamine, 1-[3-(2,3-dichlorophenyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl]-4-methyl- | 英文名 | 4-Piperidinamine, 1-[3-(2,3-dichlorophenyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl]-4-methyl- |
|---|---|---|---|---|
| CAS号 | 2160546-07-4 | 分子量 | 377.27 | |
| 密度 | N/A | 沸点 | N/A | |
| 分子式 | C17H18Cl2N6 | 熔点 | N/A | |
| MSDS | N/A | 闪点 | N/A |
用途IACS-13909 is a specific and potent allosteric inhibitor of SHP2 that suppresses the signaling of RTK/MAPK pathway and overcomes multiple mechanisms underlying osimertinib resistance. IACS-13909 potently impedes the proliferation of tumors with a broad spectrum of RTKs as the oncogenic driver. Importantly, in NSCLC models with acquired resistance to osimertinib, IACS-13909 administered as a single agent or in combination with osimertinib potently reduces tumor cell proliferation in vitro and in vivo. Together, our findings provide preclinical evidence for using a SHP2 inhibitor as a therapeutic strategy in acquired EGFR inhibitor-resistant NSCLC. |
| 英文名 | IACS-13909 |
|---|---|
| 英文别名 | 更多 |
| 分子式 | C17H18Cl2N6 |
|---|---|
| 分子量 | 377.27 |
| 储存条件 | -20°C |
| 4-Piperidinamine, 1-[3-(2,3-dichlorophenyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl]-4-methyl- |